Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | SOAT2 | O75908 | 2/20 | 0.52 |
| ▸ | SOAT1 | P35610 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.43 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6899771 | 0.87 | SOAT1 (0.62) | SOAT2SOAT1SMN1; SMN2LMNAKMT2A | |
| SCHEMBL9844078 | 0.86 | SOAT1 (0.56) | SOAT2SOAT1ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL13328398 | 0.85 | SOAT2 (0.55) | SOAT2SOAT1SMN1; SMN2LMNAKMT2A | |
| SCHEMBL2147650 | 0.78 | KMT2A (0.65) | SOAT2SOAT1SMN1; SMN2LMNAKMT2A | |
| SCHEMBL11143056 | 0.76 | ALDH1A1 (0.58) | SOAT2SOAT1ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL9681145 | 0.76 | SOAT2 (0.56) | SOAT2SOAT1ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL9844236 | 0.75 | SMN1; SMN2 (0.57) | SOAT2SOAT1SMN1; SMN2LMNAKMT2A | |
| SCHEMBL13472622 | 0.74 | POLB (0.62) | POLBALDH1A1GAATP53LIMK1 | |
| SCHEMBL9680211 | 0.74 | SOAT2 (0.52) | SOAT2SOAT1ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL9679656 | 0.74 | SOAT2 (0.60) | SOAT2SOAT1SMN1; SMN2LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0433662-A2 | Acat inhibitors | WARNER-LAMBERT COMPANY (US) | 1991-06-26 | — | — | EP | claimed |
| US-20130178446-A1 | METHOD FOR DECREASING SEBUM PRODUCTION | MEDICIS PHARMACEUTICAL CORPORATION (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130178446-A1 | METHOD FOR DECREASING SEBUM PRODUCTION | MEDICIS PHARMACEUTICAL CORPORATION (US) | 2013-07-11 | — | — | US | disclosed |
| US-8409595-B2 | Method for decreasing sebum production | MEDICIS PHARMACEUTICAL CORPORATION (US) | 2013-04-02 | — | — | US | disclosed |
| US-8409595-B2 | Method for decreasing sebum production | MEDICIS PHARMACEUTICAL CORPORATION (US) | 2013-04-02 | — | — | US | disclosed |
| US-20100113601-A1 | METHOD FOR DECREASING SEBUM PRODUCTION | GRACEWAY PHARMACEUTICALS, LLC (US) | 2010-05-06 | — | — | US | disclosed |
| US-20100113601-A1 | METHOD FOR DECREASING SEBUM PRODUCTION | GRACEWAY PHARMACEUTICALS, LLC (US) | 2010-05-06 | — | — | US | disclosed |
| US-7615230-B2 | Topical applying N-benzyl-N'-(2,6-diisopropyl-phenyl)-N-isopropyl-malonamide as ACAT inhibitor to treat oily skin; acylcoenzyme a cholesterol acyltransferase (ACAT) | GRACEWAY PHARMACEUTICALS, LLC (US) | 2009-11-10 | — | — | US | disclosed |
| US-7615230-B2 | Topical applying N-benzyl-N'-(2,6-diisopropyl-phenyl)-N-isopropyl-malonamide as ACAT inhibitor to treat oily skin; acylcoenzyme a cholesterol acyltransferase (ACAT) | GRACEWAY PHARMACEUTICALS, LLC (US) | 2009-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178446-A1 | METHOD FOR DECREASING SEBUM PRODUCTION | ACAT2, ACAT1, ACOT7 | POLB 2694/4885SOAT2 28/4885SOAT1 17/4885 |
| US-20100113601-A1 | METHOD FOR DECREASING SEBUM PRODUCTION | ACAT2, ACAT1, ACOT7 | POLB 2694/4885SOAT2 28/4885SOAT1 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.